In mice with metabolic disease, a constant increase in the acetylation level of FXR prevents the heterodimerization of FXR/RXRα, as well as the DNA binding of FXR/RXRα, leading to a reduction in the transactivation of FXR metabolic target genes. Here, NR1H4 is linked to metabolic disease.